Parkinson’s disease (PD) affects 6 million people worldwide and is the second-leading neurodegenerative disease. The U.S. economic burden for PD in 2019 was estimated to be $52 billion. While there are current treatments for PD that offer symptomatic relief, there are no FDA-approved therapeutics to slow disease progression or address the underlying disease mechanism. In preclinical research, Axial has established the contributory effect of certain gut bacteria, specifically through the production of bacterial amyloids, to gastrointestinal (GI) symptoms, motor symptoms, and disease pathology in PD.

​

Axial is in preclinical development with AB-5006, a potent new chemical entity (NCE), focused on reducing bacterial amyloid aggregation in the gut and attenuating disease progression in PD.